Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hepatitis

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 429 articles:
HTML format
Text format



Single Articles


    January 2019
  1. FOSTER GR, Asselah T, Kopecky-Bromberg S, Lei Y, et al
    Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
    PLoS One. 2019;14:e0208506.
    PubMed     Text format     Abstract available


  2. POPPING S, Hullegie SJ, Boerekamps A, Rijnders BJA, et al
    Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men.
    PLoS One. 2019;14:e0210179.
    PubMed     Text format     Abstract available


  3. YEN YH, Kee KM, Chen CH, Hu TH, et al
    Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C.
    PLoS One. 2019;14:e0208858.
    PubMed     Text format     Abstract available


  4. BRENNER N, Mentzer AJ, Butt J, Braband KL, et al
    Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.
    PLoS One. 2019;14:e0210407.
    PubMed     Text format     Abstract available


  5. KONERMAN MA, Beste LA, Van T, Liu B, et al
    Machine learning models to predict disease progression among veterans with hepatitis C virus.
    PLoS One. 2019;14:e0208141.
    PubMed     Text format     Abstract available


  6. SHTEYER E, Shekhtman L, Zinger T, Harari S, et al
    Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography.
    PLoS One. 2019;14:e0210173.
    PubMed     Text format     Abstract available


  7. MANE A, Sacks J, Sharma S, Singh H, et al
    Evaluation of five rapid diagnostic tests for detection of antibodies to hepatitis C virus (HCV): A step towards scale-up of HCV screening efforts in India.
    PLoS One. 2019;14:e0210556.
    PubMed     Text format     Abstract available


  8. XIAO Y, Shen M, Ma S, Wen SW, et al
    The association between inter-twin birth weight discordance and hepatitis C: The United States 2011-2015 twin birth registration data.
    PLoS One. 2019;14:e0211683.
    PubMed     Text format     Abstract available


  9. SHILI-MASMOUDI S, Sogni P, de Ledinghen V, Esterle L, et al
    Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.
    PLoS One. 2019;14:e0211286.
    PubMed     Text format     Abstract available


  10. SHTEYER E, Shekhtman L, Zinger T, Harari S, et al
    Correction: Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography.
    PLoS One. 2019;14:e0212252.
    PubMed     Text format     Abstract available


  11. SHENGE JA, Odaibo GN, Olaleye DO
    Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria.
    PLoS One. 2019;14:e0210724.
    PubMed     Text format     Abstract available


  12. ANABIRE NG, Aryee PA, Abdul-Karim A, Abdulai IB, et al
    Prevalence of malaria and hepatitis B among pregnant women in Northern Ghana: Comparing RDTs with PCR.
    PLoS One. 2019;14:e0210365.
    PubMed     Text format     Abstract available


  13. ARENDS RM, Nelwan EJ, Soediro R, van Crevel R, et al
    Associations between impulsivity, risk behavior and HIV, HBV, HCV and syphilis seroprevalence among female prisoners in Indonesia: A cross-sectional study.
    PLoS One. 2019;14:e0207970.
    PubMed     Text format     Abstract available


  14. YANG RF, Liu Y, Zhao CY, Ding YX, et al
    A novel point-of-care oral anti-HCV assay: Is it reliable for screening hepatitis C virus infection in the era of direct-acting antivirals?
    PLoS One. 2019;14:e0211795.
    PubMed     Text format     Abstract available


  15. HANSEN JF, Christiansen KM, Staugaard B, Moessner BK, et al
    Combining liver stiffness with hyaluronic acid provides superior prognostic performance in chronic hepatitis C.
    PLoS One. 2019;14:e0212036.
    PubMed     Text format     Abstract available


  16. REUSCHEL E, Jilg W, Seelbach-Goebel B, Deml L, et al
    Comparative purification and characterization of hepatitis B virus-like particles produced by recombinant vaccinia viruses in human hepatoma cells and human primary hepatocytes.
    PLoS One. 2019;14:e0212800.
    PubMed     Text format     Abstract available


  17. SKOGLUND C, Lagging M, Castedal M
    No need to discontinue hepatitis C virus therapy at the time of liver transplantation.
    PLoS One. 2019;14:e0211437.
    PubMed     Text format     Abstract available


  18. PETRUZZIELLO A, Sabatino R, Loquercio G, Guzzo A, et al
    Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy.
    PLoS One. 2019;14:e0212033.
    PubMed     Text format     Abstract available


  19. TAKEUCHI F, Ikeda S, Tsukamoto Y, Iwasawa Y, et al
    Screening for inhibitor of episomal DNA identified dicumarol as a hepatitis B virus inhibitor.
    PLoS One. 2019;14:e0212233.
    PubMed     Text format     Abstract available


  20. VILLAR LM, Geloneze B, Vasques ACJ, Pires MLE, et al
    Prevalence of hepatitis B and hepatitis C among diabetes mellitus type 2 individuals.
    PLoS One. 2019;14:e0211193.
    PubMed     Text format     Abstract available


  21. JANG Y, Ahn SH, Lee K, Lee J, et al
    Psychometric evaluation of the Korean version of the Hepatitis B Quality of Life Questionnaire.
    PLoS One. 2019;14:e0213001.
    PubMed     Text format     Abstract available


  22. GRANADOS-GARCIA V, Flores YN, Diaz-Trejo LI, Mendez-Sanchez L, et al
    Estimating the prevalence of hepatitis C among intravenous drug users in upper middle income countries: A systematic review and meta-analysis.
    PLoS One. 2019;14:e0212558.
    PubMed     Text format     Abstract available


  23. GANOVA-RAEVA L, Dimitrova Z, Alexiev I, Punkova L, et al
    HCV transmission in high-risk communities in Bulgaria.
    PLoS One. 2019;14:e0212350.
    PubMed     Text format     Abstract available


  24. JONES EA, Linas BP, Truong V, Burgess JF, et al
    Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
    PLoS One. 2019;14:e0213745.
    PubMed     Text format     Abstract available


  25. CHIU SY, Chung HJ, Chen YT, Huang MS, et al
    A nonsense mutant of the hepatitis B virus large S protein antagonizes multiple tumor suppressor pathways through c-Jun activation domain-binding protein1.
    PLoS One. 2019;14:e0208665.
    PubMed     Text format     Abstract available


  26. LE NGOC C, Tran Thi Thanh T, Tran Thi Lan P, Nguyen Mai T, et al
    Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam.
    PLoS One. 2019;14:e0212734.
    PubMed     Text format     Abstract available


  27. HUANG CH, Wu LS, Jeng WJ, Cheng YF, et al
    In HCV-related liver cirrhosis, local pulse wave velocity increases and in decompensated patients correlates with poorer survival.
    PLoS One. 2019;14:e0212770.
    PubMed     Text format     Abstract available


  28. WIBABARA Y, Banura C, Kalyango J, Karamagi C, et al
    Hepatitis B vaccination status and associated factors among undergraduate students of Makerere University College of Health Sciences.
    PLoS One. 2019;14:e0214732.
    PubMed     Text format     Abstract available


  29. BUGGISCH P, Wursthorn K, Stoehr A, Atanasov PK, et al
    Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    PLoS One. 2019;14:e0214795.
    PubMed     Text format     Abstract available


  30. AHSAN A, Khan AZ, Javed H, Mirza S, et al
    Estimation of hepatitis C prevalence in the Punjab province of Pakistan: A retrospective study on general population.
    PLoS One. 2019;14:e0214435.
    PubMed     Text format     Abstract available


  31. LEE YC, Hu TH, Hung CH, Lu SN, et al
    The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals.
    PLoS One. 2019;14:e0214323.
    PubMed     Text format     Abstract available


  32. PETRUZZIELLO A, Sabatino R, Loquercio G, Guzzo A, et al
    Correction: Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy.
    PLoS One. 2019;14:e0215559.
    PubMed     Text format     Abstract available


  33. HANG PHAM TT, Le TX, Nguyen DT, Luu CM, et al
    Knowledge, attitudes and practices of hepatitis B prevention and immunization of pregnant women and mothers in northern Vietnam.
    PLoS One. 2019;14:e0208154.
    PubMed     Text format     Abstract available


  34. RAJAMOORTHY Y, Radam A, Taib NM, Rahim KA, et al
    Willingness to pay for hepatitis B vaccination in Selangor, Malaysia: A cross-sectional household survey.
    PLoS One. 2019;14:e0215125.
    PubMed     Text format     Abstract available


  35. ANABIRE NG, Aryee PA, Abdul-Karim A, Quaye O, et al
    Impact of malaria and hepatitis B co-infection on clinical and cytokine profiles among pregnant women.
    PLoS One. 2019;14:e0215550.
    PubMed     Text format     Abstract available


  36. BOATENG R, Mutocheluh M, Dompreh A, Obiri-Yeboah D, et al
    Sero-prevalence of Hepatitis B and C viral co-infections among HIV-1 infected ART-naive individuals in Kumasi, Ghana.
    PLoS One. 2019;14:e0215377.
    PubMed     Text format     Abstract available


  37. LATTHAPHASAVANG V, Vanhems P, Ngo-Giang-Huong N, Sibounlang P, et al
    Perinatal hepatitis B virus transmission in Lao PDR: A prospective cohort study.
    PLoS One. 2019;14:e0215011.
    PubMed     Text format     Abstract available


  38. MIAO N, Zheng H, Sun X, Shen L, et al
    Enhanced sentinel surveillance for hepatitis B infection in 200 counties in China, 2013-2016.
    PLoS One. 2019;14:e0215580.
    PubMed     Text format     Abstract available



  39. Retraction: Role of Hepatitis C Virus Induced Osteopontin in Epithelial to Mesenchymal Transition, Migration and Invasion of Hepatocytes.
    PLoS One. 2019;14:e0216026.
    PubMed     Text format    



  40. Retraction: Activation of TGF-beta1 Promoter by Hepatitis C Virus-Induced AP-1 and Sp1: Role of TGF-beta1 in Hepatic Stellate Cell Activation and Invasion.
    PLoS One. 2019;14:e0216025.
    PubMed     Text format    


  41. CHIKOVANI I, Ompad DC, Uchaneishvili M, Sulaberidze L, et al
    On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study.
    PLoS One. 2019;14:e0216123.
    PubMed     Text format     Abstract available


  42. MPODY C, Thompson P, Tabala M, Ravelomanana NLR, et al
    Hepatitis B infection among pregnant and post-partum women living with HIV and on antiretroviral therapy in Kinshasa, DR Congo: A cross-sectional study.
    PLoS One. 2019;14:e0216293.
    PubMed     Text format     Abstract available


  43. YUAN Q, Wang F, Zheng H, Zhang G, et al
    Hepatitis B vaccination coverage among health care workers in China.
    PLoS One. 2019;14:e0216598.
    PubMed     Text format     Abstract available


  44. COSTA VD, Brandao-Mello CE, Nunes EP, Dos Santos Silva PGC, et al
    Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
    PLoS One. 2019;14:e0216327.
    PubMed     Text format     Abstract available


  45. COSSAIS S, Schwarzinger M, Pol S, Fontaine H, et al
    Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage.
    PLoS One. 2019;14:e0215596.
    PubMed     Text format     Abstract available


  46. CHEN M, Ma Y, Chen H, Dai J, et al
    Complete genome sequencing and evolutionary analysis of HCV subtype 6xg from IDUs in Yunnan, China.
    PLoS One. 2019;14:e0217010.
    PubMed     Text format     Abstract available


  47. MANGIA A, Piazzolla V, Giannelli A, Visaggi E, et al
    SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
    PLoS One. 2019;14:e0215783.
    PubMed     Text format     Abstract available


  48. GEBOY AG, Nichols WL, Fernandez SJ, Desale S, et al
    Leveraging the electronic health record to eliminate hepatitis C: Screening in a large integrated healthcare system.
    PLoS One. 2019;14:e0216459.
    PubMed     Text format     Abstract available


  49. WILHELM B, Waddell L, Greig J, Young I, et al
    Systematic review and meta-analysis of the seroprevalence of hepatitis E virus in the general population across non-endemic countries.
    PLoS One. 2019;14:e0216826.
    PubMed     Text format     Abstract available


  50. CHAILLON A, Mehta SR, Hoenigl M, Solomon SS, et al
    Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection.
    PLoS One. 2019;14:e0217964.
    PubMed     Text format     Abstract available


  51. GASTALDI G, Gomes D, Schneiter P, Montet X, et al
    Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients.
    PLoS One. 2019;14:e0217751.
    PubMed     Text format     Abstract available


  52. ROBERTS H, Boktor SW, Waller K, Daar ZS, et al
    Underreporting of Hepatitis B and C virus infections - Pennsylvania, 2001-2015.
    PLoS One. 2019;14:e0217455.
    PubMed     Text format     Abstract available


  53. MEDIC S, Anastassopoulou C, Milosevic V, Dragnic N, et al
    Declining seroprevalence of hepatitis A in Vojvodina, Serbia.
    PLoS One. 2019;14:e0217176.
    PubMed     Text format     Abstract available


  54. COFFIN PO, Santos GM, Behar E, Hern J, et al
    Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs.
    PLoS One. 2019;14:e0217471.
    PubMed     Text format     Abstract available


  55. RODRIGUEZ-OSORIO I, Mena A, Meijide H, Morano L, et al
    Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals.
    PLoS One. 2019;14:e0217052.
    PubMed     Text format     Abstract available


  56. PRABDIAL-SING N, Makhathini L, Smit SB, Manamela MJ, et al
    Hepatitis B sero-prevalence in children under 15 years of age in South Africa using residual samples from community-based febrile rash surveillance.
    PLoS One. 2019;14:e0217415.
    PubMed     Text format     Abstract available


  57. FURUTANI Y, Toguchi M, Shiozaki-Sato Y, Qin XY, et al
    An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes.
    PLoS One. 2019;14:e0216139.
    PubMed     Text format     Abstract available


  58. PAVICIC IVELJA M, Ivic I, Dolic K, Mestrovic A, et al
    Evaluation of cerebrovascular reactivity in chronic hepatitis C patients using transcranial color Doppler.
    PLoS One. 2019;14:e0218206.
    PubMed     Text format     Abstract available


  59. BAROCAS JA, So-Armah K, Cheng DM, Lioznov D, et al
    Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naive persons with alcohol use in Russia.
    PLoS One. 2019;14:e0218852.
    PubMed     Text format     Abstract available


  60. IZQUIERDO L, Mellon G, Buchaillet C, Fac C, et al
    Prevalence of hepatitis E virus and reassessment of HIV and other hepatitis virus seroprevalences among French prison inmates.
    PLoS One. 2019;14:e0218482.
    PubMed     Text format     Abstract available


  61. HAERI MAZANDERANI A, Motaze NV, McCarthy K, Suchard M, et al
    Hepatitis A virus seroprevalence in South Africa - Estimates using routine laboratory data, 2005-2015.
    PLoS One. 2019;14:e0216033.
    PubMed     Text format     Abstract available


  62. BREZZI M, Bertisch B, Roelens M, Moradpour D, et al
    Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study.
    PLoS One. 2019;14:e0218706.
    PubMed     Text format     Abstract available


  63. OBIRI-YEBOAH D, Awuku YA, Adjei G, Cudjoe O, et al
    Post Hepatitis B vaccination sero-conversion among health care workers in the Cape Coast Metropolis of Ghana.
    PLoS One. 2019;14:e0219148.
    PubMed     Text format     Abstract available


  64. RAIHAN R, Akbar SMF, Al Mahtab M, Takahashi K, et al
    Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh.
    PLoS One. 2019;14:e0218744.
    PubMed     Text format     Abstract available


  65. CAMMAROTA S, Citarella A, Guida A, Conti V, et al
    The inpatient hospital burden of comorbidities in HCV-infected patients: A population-based study in two Italian regions with high HCV endemicity (The BaCH study).
    PLoS One. 2019;14:e0219396.
    PubMed     Text format     Abstract available


  66. KATO K, Shimada N, Atsukawa M, Abe H, et al
    Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.
    PLoS One. 2019;14:e0219022.
    PubMed     Text format     Abstract available


  67. CALNER P, Sperring H, Ruiz-Mercado G, Miller NS, et al
    HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center.
    PLoS One. 2019;14:e0218388.
    PubMed     Text format     Abstract available


  68. LAWANDI A, Cheng MP, Lee TC
    Hepatitis B testing practices at a tertiary care centre and their associated costs: A retrospective analysis.
    PLoS One. 2019;14:e0219347.
    PubMed     Text format     Abstract available


  69. FREMPONG MT, Ntiamoah P, Annani-Akollor ME, Owiredu WKBA, et al
    Hepatitis B and C infections in HIV-1 and non-HIV infected pregnant women in the Brong-Ahafo Region, Ghana.
    PLoS One. 2019;14:e0219922.
    PubMed     Text format     Abstract available


  70. BASKIC D, Vukovic V, Popovic S, Jovanovic D, et al
    Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution.
    PLoS One. 2019;14:e0219508.
    PubMed     Text format     Abstract available


  71. JULICHER P, Chulanov VP, Pimenov NN, Chirkova E, et al
    Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis.
    PLoS One. 2019;14:e0219687.
    PubMed     Text format     Abstract available



  72. Retraction: Downgrading MELD Improves the Outcomes after Liver Transplantation in Patients with Acute-on-Chronic Hepatitis B Liver Failure.
    PLoS One. 2019;14:e0220487.
    PubMed     Text format    


  73. WANG M, Wang Y, Liu Y, Wang H, et al
    SPSB2 inhibits hepatitis C virus replication by targeting NS5A for ubiquitination and degradation.
    PLoS One. 2019;14:e0219989.
    PubMed     Text format     Abstract available


  74. SPITZ N, Mello FCA, Moreira AS, Gusatti CS, et al
    Reconstruction of the spatial and temporal dynamics of hepatitis B virus genotype D in the Americas.
    PLoS One. 2019;14:e0220342.
    PubMed     Text format     Abstract available


  75. CHEN X, Chen Y, Liu C, Li X, et al
    Improved one-tube RT-PCR method for simultaneous detection and genotyping of duck hepatitis A virus subtypes 1 and 3.
    PLoS One. 2019;14:e0219750.
    PubMed     Text format     Abstract available


  76. PODLAHA O, Wu G, Downie B, Ramamurthy R, et al
    Genomic modeling of hepatitis B virus integration frequency in the human genome.
    PLoS One. 2019;14:e0220376.
    PubMed     Text format     Abstract available


  77. SOHOLM J, Holm DK, Mossner B, Madsen LW, et al
    Incidence, prevalence and risk factors for hepatitis C in Danish prisons.
    PLoS One. 2019;14:e0220297.
    PubMed     Text format     Abstract available


  78. YEH ML, Huang CF, Huang CI, Dai CY, et al
    Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients.
    PLoS One. 2019;14:e0220663.
    PubMed     Text format     Abstract available


  79. BASKIC D, Vukovic V, Popovic S, Jovanovic D, et al
    Correction: Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution.
    PLoS One. 2019;14:e0221142.
    PubMed     Text format     Abstract available


    January 2018
  80. KONDILI LA, Gaeta GB, Ieluzzi D, Zignego AL, et al
    Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    PLoS One. 2018;13:e0190803.
    PubMed     Text format     Abstract available


  81. CHARRE C, Cotte L, Kramer R, Miailhes P, et al
    Hepatitis C virus spread from HIV-positive to HIV-negative men who have sex with men.
    PLoS One. 2018;13:e0190340.
    PubMed     Text format     Abstract available


  82. CHEN SH, Lai HC, Chiang IP, Su WP, et al
    Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C.
    PLoS One. 2018;13:e0190455.
    PubMed     Text format     Abstract available


  83. LEE CS, Jung YJ, Kim SS, Cheong JY, et al
    Liver volume-based prediction model stratifies risks for hepatocellular carcinoma in chronic hepatitis B patients on surveillance.
    PLoS One. 2018;13:e0190261.
    PubMed     Text format     Abstract available


  84. CARIMO AA, Gudo ES, Maueia C, Mabunda N, et al
    First report of occult hepatitis B infection among ART naive HIV seropositive individuals in Maputo, Mozambique.
    PLoS One. 2018;13:e0190775.
    PubMed     Text format     Abstract available


  85. BIVIGOU-MBOUMBA B, Amougou-Atsama M, Zoa-Assoumou S, M'boyis Kamdem H, et al
    Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.
    PLoS One. 2018;13:e0190592.
    PubMed     Text format     Abstract available


  86. FARSHADPOUR F, Taherkhani R, Ravanbod MR, Eghbali SS, et al
    Prevalence, risk factors and molecular evaluation of hepatitis E virus infection among pregnant women resident in the northern shores of Persian Gulf, Iran.
    PLoS One. 2018;13:e0191090.
    PubMed     Text format     Abstract available


  87. LEE HJ, Kim SJ, Kweon YO, Park SY, et al
    Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.
    PLoS One. 2018;13:e0190581.
    PubMed     Text format     Abstract available


  88. MAROT A, Dubois M, Trepo E, Moreno C, et al
    Liver transplantation for alcoholic hepatitis: A systematic review with meta-analysis.
    PLoS One. 2018;13:e0190823.
    PubMed     Text format     Abstract available


  89. OBIRI-YEBOAH D, Asante Awuku Y, Adu J, Pappoe F, et al
    Sero-prevalence and risk factors for hepatitis E virus infection among pregnant women in the Cape Coast Metropolis, Ghana.
    PLoS One. 2018;13:e0191685.
    PubMed     Text format     Abstract available


  90. HEIL J, Hoebe CJPA, Loo IHMV, Cals JWL, et al
    Hepatitis E prevalence in a sexual high-risk population compared to the general population.
    PLoS One. 2018;13:e0191798.
    PubMed     Text format     Abstract available


  91. BOLOTIN S, Feld JJ, Garber G, Wong WWL, et al
    Population-based estimate of hepatitis C virus prevalence in Ontario, Canada.
    PLoS One. 2018;13:e0191184.
    PubMed     Text format     Abstract available


  92. CHENG CH, Lin CC, Chen HL, Lin IT, et al
    Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection.
    PLoS One. 2018;13:e0191799.
    PubMed     Text format     Abstract available


  93. DEL CAMPO JA, Garcia-Valdecasas M, Gil-Gomez A, Rojas A, et al
    Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.
    PLoS One. 2018;13:e0191805.
    PubMed     Text format     Abstract available


  94. NDJOYI-MBIGUINO A, Kombe Kombe AJ, Bivigou-Mboumba B, Zoa-Assoumou S, et al
    Low prevalence of HCV infection with predominance of genotype 4 among HIV patients living in Libreville, Gabon.
    PLoS One. 2018;13:e0190529.
    PubMed     Text format     Abstract available


  95. SAFREED-HARMON K, Hetherington KL, Aleman S, Alho H, et al
    Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.
    PLoS One. 2018;13:e0190146.
    PubMed     Text format     Abstract available


  96. ZAHR NM
    Peripheral TNFalpha elevations in abstinent alcoholics are associated with hepatitis C infection.
    PLoS One. 2018;13:e0191586.
    PubMed     Text format     Abstract available


  97. DE PINA-ARAUJO IIM, Spitz N, Soares CC, Niel C, et al
    Hepatitis B virus genotypes A1, A2 and E in Cape Verde: Unequal distribution through the islands and association with human flows.
    PLoS One. 2018;13:e0192595.
    PubMed     Text format     Abstract available


  98. HUGHES E, Hopkins LJ, Parker R
    Survival from alcoholic hepatitis has not improved over time.
    PLoS One. 2018;13:e0192393.
    PubMed     Text format     Abstract available


  99. KELLY ML, Riordan SM, Bopage R, Lloyd AR, et al
    Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study.
    PLoS One. 2018;13:e0192763.
    PubMed     Text format     Abstract available


  100. ANADOL E, Lust K, Boesecke C, Schwarze-Zander C, et al
    Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients.
    PLoS One. 2018;13:e0191118.
    PubMed     Text format     Abstract available


  101. RATTANAVIPAPONG W, Anothaisintawee T, Teerawattananon Y
    Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis.
    PLoS One. 2018;13:e0193112.
    PubMed     Text format     Abstract available


  102. TARAMASSO L, Di Biagio A, Bovis F, Nicolini LA, et al
    Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir +/- ribavirin in HIV/HCV co-infected patients.
    PLoS One. 2018;13:e0192627.
    PubMed     Text format     Abstract available


  103. AMBACHEW H, Zheng M, Pappoe F, Shen J, et al
    Genotyping and sero-virological characterization of hepatitis B virus (HBV) in blood donors, Southern Ethiopia.
    PLoS One. 2018;13:e0193177.
    PubMed     Text format     Abstract available


  104. CHENG PN, Chiu YC, Chiu HC, Chien SC, et al
    The characteristics of residents with unawareness of hepatitis C virus infection in community.
    PLoS One. 2018;13:e0193251.
    PubMed     Text format     Abstract available


  105. MAPOURE NY, Budzi MN, Eloumou SAFB, Malongue A, et al
    Neurological manifestations in chronic hepatitis C patients receiving care in a reference hospital in sub-Saharan Africa: A cross-sectional study.
    PLoS One. 2018;13:e0192406.
    PubMed     Text format     Abstract available


  106. BALSITIS S, Gali V, Mason PJ, Chaniewski S, et al
    Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection.
    PLoS One. 2018;13:e0190058.
    PubMed     Text format     Abstract available


  107. MAUNOURY F, Clement A, Nwankwo C, Levy-Bachelot L, et al
    Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
    PLoS One. 2018;13:e0194329.
    PubMed     Text format     Abstract available


  108. AN J, Kim JW, Shim JH, Han S, et al
    Chronic hepatitis B infection and non-hepatocellular cancers: A hospital registry-based, case-control study.
    PLoS One. 2018;13:e0193232.
    PubMed     Text format     Abstract available


  109. DI POTO C, He S, Varghese RS, Zhao Y, et al
    Identification of race-associated metabolite biomarkers for hepatocellular carcinoma in patients with liver cirrhosis and hepatitis C virus infection.
    PLoS One. 2018;13:e0192748.
    PubMed     Text format     Abstract available


  110. MOTOYAMA H, Tamori A, Kubo S, Uchida-Kobayashi S, et al
    Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
    PLoS One. 2018;13:e0194163.
    PubMed     Text format     Abstract available


  111. ZEKRI AN, El-Sisi ER, Youssef ASE, Kamel MM, et al
    MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection.
    PLoS One. 2018;13:e0193709.
    PubMed     Text format     Abstract available


  112. CARABALLO CORTES K, Rosinska M, Janiak M, Stepien M, et al
    Next-generation sequencing analysis of a cluster of hepatitis C virus infections in a haematology and oncology center.
    PLoS One. 2018;13:e0194816.
    PubMed     Text format     Abstract available


  113. SAUVAGE V, Boizeau L, Candotti D, Vandenbogaert M, et al
    Early MinION nanopore single-molecule sequencing technology enables the characterization of hepatitis B virus genetic complexity in clinical samples.
    PLoS One. 2018;13:e0194366.
    PubMed     Text format     Abstract available


  114. NEMOZ B, Roger L, Leroy V, Poveda JD, et al
    Evaluation of the cobas(R) GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures.
    PLoS One. 2018;13:e0194396.
    PubMed     Text format     Abstract available


  115. NGUYEN HH, Shaheen AA, Baeza N, Lytvyak E, et al
    Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS).
    PLoS One. 2018;13:e0193960.
    PubMed     Text format     Abstract available


  116. LI CW, Yang CJ, Sun HY, Tsai MS, et al
    Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan.
    PLoS One. 2018;13:e0194149.
    PubMed     Text format     Abstract available


  117. BRAND RF, Rostal MK, Kemp A, Anyamba A, et al
    A phytosociological analysis and description of wetland vegetation and ecological factors associated with locations of high mortality for the 2010-11 Rift Valley fever outbreak in South Africa.
    PLoS One. 2018;13:e0191585.
    PubMed     Text format     Abstract available


  118. DES JARLAIS DC, Cooper HLF, Arasteh K, Feelemyer J, et al
    Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US.
    PLoS One. 2018;13:e0194799.
    PubMed     Text format     Abstract available



  119. Retraction: rs10499194 polymorphism in the tumor necrosis factor-alpha inducible protein 3 (TNFAIP3) gene is associated with type-1 autoimmune hepatitis risk in Chinese Han population.
    PLoS One. 2018;13:e0195181.
    PubMed     Text format    


  120. TI L, Socias ME, Wood E, Milloy MJ, et al
    The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs.
    PLoS One. 2018;13:e0194162.
    PubMed     Text format     Abstract available


  121. KHAN T, Zaman G, Saleh Alshomrani A
    Spreading dynamic of acute and carrier hepatitis B with nonlinear incidence.
    PLoS One. 2018;13:e0191914.
    PubMed     Text format     Abstract available


  122. YAMAZAKI T, Joshita S, Umemura T, Usami Y, et al
    Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.
    PLoS One. 2018;13:e0195632.
    PubMed     Text format     Abstract available


  123. GOLIZEH M, Melendez-Pena CE, Ward BJ, Saeed S, et al
    Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging.
    PLoS One. 2018;13:e0195148.
    PubMed     Text format     Abstract available


  124. BELYHUN Y, Liebert UG, Maier M
    Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia.
    PLoS One. 2018;13:e0191970.
    PubMed     Text format     Abstract available


  125. DE LA FUENTE C, Pinkham C, Dabbagh D, Beitzel B, et al
    Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection.
    PLoS One. 2018;13:e0191983.
    PubMed     Text format     Abstract available


  126. EKO MBA JM, Bisseye C, Ntsame Ndong JM, Mombo LE, et al
    Prevalent hepatitis B surface antigen among first-time blood donors in Gabon.
    PLoS One. 2018;13:e0194285.
    PubMed     Text format     Abstract available


  127. HAN B, Yuan Q, Shi Y, Wei L, et al
    The experience of discrimination of individuals living with chronic hepatitis B in four provinces of China.
    PLoS One. 2018;13:e0195455.
    PubMed     Text format     Abstract available


  128. FACENTE SN, Grebe E, Burk K, Morris MD, et al
    Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.
    PLoS One. 2018;13:e0195575.
    PubMed     Text format     Abstract available


  129. FRIEDMAN A, Siewe N
    Chronic hepatitis B virus and liver fibrosis: A mathematical model.
    PLoS One. 2018;13:e0195037.
    PubMed     Text format     Abstract available


  130. HUGHES E, Hopkins LJ, Parker R
    Correction: Survival from alcoholic hepatitis has not improved over time.
    PLoS One. 2018;13:e0195857.
    PubMed     Text format     Abstract available


  131. LU Y, Jin X, Duan CA, Chang F, et al
    Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naive patients in China.
    PLoS One. 2018;13:e0195117.
    PubMed     Text format     Abstract available


  132. HAMADA K, Saitoh S, Nishino N, Fukushima D, et al
    Shear wave elastography predicts hepatocellular carcinoma risk in hepatitis C patients after sustained virological response.
    PLoS One. 2018;13:e0195173.
    PubMed     Text format     Abstract available


  133. MASHIBA T, Joko K, Kurosaki M, Ochi H, et al
    Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
    PLoS One. 2018;13:e0194704.
    PubMed     Text format     Abstract available


  134. FISHER KA, Cahill LM, Broyles S, Rorke M, et al
    Knowledge of hepatitis C status moderates the relationship between history of drug treatment and sterile syringe use.
    PLoS One. 2018;13:e0196157.
    PubMed     Text format     Abstract available


  135. CHIU YM, Lai MS, Chan KA
    Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.
    PLoS One. 2018;13:e0196210.
    PubMed     Text format     Abstract available


  136. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    PLoS One. 2018;13:e0196301.
    PubMed     Text format     Abstract available


  137. OKUBO H, Ando H, Sorin Y, Nakadera E, et al
    Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C.
    PLoS One. 2018;13:e0196747.
    PubMed     Text format     Abstract available


  138. PARK H, Jeong D, Nguyen P, Henry L, et al
    Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis.
    PLoS One. 2018;13:e0196452.
    PubMed     Text format     Abstract available


  139. JIMENEZ-SOUSA MA, Gomez-Moreno AZ, Pineda-Tenor D, Medrano LM, et al
    The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design.
    PLoS One. 2018;13:e0197115.
    PubMed     Text format     Abstract available


  140. DEMSISS W, Seid A, Fiseha T
    Hepatitis B and C: Seroprevalence, knowledge, practice and associated factors among medicine and health science students in Northeast Ethiopia.
    PLoS One. 2018;13:e0196539.
    PubMed     Text format     Abstract available


  141. FENG Y, Feng YM, Wang S, Xu F, et al
    High seroprevalence of hepatitis E virus in the ethnic minority populations in Yunnan, China.
    PLoS One. 2018;13:e0197577.
    PubMed     Text format     Abstract available


  142. TSUKAMOTO Y, Ikeda S, Uwai K, Taguchi R, et al
    Rosmarinic acid is a novel inhibitor for Hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction.
    PLoS One. 2018;13:e0197664.
    PubMed     Text format     Abstract available


  143. MAWATARI S, Oda K, Tabu K, Ijuin S, et al
    The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.
    PLoS One. 2018;13:e0198642.
    PubMed     Text format     Abstract available


  144. YAMAMIYA D, Mizukoshi E, Kaji K, Terashima T, et al
    Immune responses of human T lymphocytes to novel hepatitis B virus-derived peptides.
    PLoS One. 2018;13:e0198264.
    PubMed     Text format     Abstract available


  145. NAKANO T, Moriya K, Koike K, Horie T, et al
    Hepatitis C virus core protein triggers abnormal porphyrin metabolism in human hepatocellular carcinoma cells.
    PLoS One. 2018;13:e0198345.
    PubMed     Text format     Abstract available


  146. BLANCO RY, Loureiro CL, Villalba JA, Sulbaran YF, et al
    Decreasing prevalence of Hepatitis B and absence of Hepatitis C Virus infection in the Warao indigenous population of Venezuela.
    PLoS One. 2018;13:e0197662.
    PubMed     Text format     Abstract available


  147. BRUNI R, Villano U, Equestre M, Chionne P, et al
    Hepatitis E virus genotypes and subgenotypes causing acute hepatitis, Bulgaria, 2013-2015.
    PLoS One. 2018;13:e0198045.
    PubMed     Text format     Abstract available


  148. GROTTENTHALER JM, Werner CR, Steurer M, Spengler U, et al
    Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
    PLoS One. 2018;13:e0197544.
    PubMed     Text format     Abstract available


  149. MULLER SF, Konig A, Doring B, Glebe D, et al
    Characterisation of the hepatitis B virus cross-species transmission pattern via Na+/taurocholate co-transporting polypeptides from 11 New World and Old World primate species.
    PLoS One. 2018;13:e0199200.
    PubMed     Text format     Abstract available


  150. ZUCKERMAN A, Douglas A, Nwosu S, Choi L, et al
    Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era.
    PLoS One. 2018;13:e0199174.
    PubMed     Text format     Abstract available


  151. HAINSWORTH SW, Dietze PM, Wilson DP, Sutton B, et al
    Hepatitis C virus notification rates in Australia are highest in socioeconomically disadvantaged areas.
    PLoS One. 2018;13:e0198336.
    PubMed     Text format     Abstract available


  152. YEN YH, Kuo FY, Kee KM, Chang KC, et al
    APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level.
    PLoS One. 2018;13:e0199760.
    PubMed     Text format     Abstract available


  153. BUTI M, Manzano ML, Morillas RM, Garcia-Retortillo M, et al
    Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.
    PLoS One. 2018;13:e0199926.
    PubMed     Text format     Abstract available


  154. YAYA I, Roux P, Marcellin F, Wittkop L, et al
    Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.
    PLoS One. 2018;13:e0199874.
    PubMed     Text format     Abstract available


  155. KIM TH, Lee EJ, Choi JH, Yim SY, et al
    Identification of novel susceptibility loci associated with hepatitis B surface antigen seroclearance in chronic hepatitis B.
    PLoS One. 2018;13:e0199094.
    PubMed     Text format     Abstract available


  156. CHEN YY, Fang WH, Wang CC, Kao TW, et al
    Increased body fat percentage in patients with hepatitis B and C virus infection.
    PLoS One. 2018;13:e0200164.
    PubMed     Text format     Abstract available


  157. SCHAEFER B, Viveiros A, Al-Zoairy R, Blach S, et al
    Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.
    PLoS One. 2018;13:e0200750.
    PubMed     Text format     Abstract available


  158. FACENTE SN, Grebe E, Burk K, Morris MD, et al
    Correction: Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.
    PLoS One. 2018;13:e0200866.
    PubMed     Text format     Abstract available


  159. ZHERNAKOVA DV, Kliver S, Cherkasov N, Tamazian G, et al
    Analytical "bake-off" of whole genome sequencing quality for the Genome Russia project using a small cohort for autoimmune hepatitis.
    PLoS One. 2018;13:e0200423.
    PubMed     Text format     Abstract available


  160. MIOTTO N, Mendes LC, Zanaga LP, Lazarini MSK, et al
    All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response.
    PLoS One. 2018;13:e0199941.
    PubMed     Text format     Abstract available


  161. MALAGNINO V, Salpini R, Maffongelli G, Battisti A, et al
    High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance.
    PLoS One. 2018;13:e0195045.
    PubMed     Text format     Abstract available


  162. TIEU HV, Laeyendecker O, Nandi V, Rose R, et al
    Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City.
    PLoS One. 2018;13:e0200269.
    PubMed     Text format     Abstract available


  163. WEI L, Wedemeyer H, Liaw YF, Chan HL, et al
    No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
    PLoS One. 2018;13:e0199198.
    PubMed     Text format     Abstract available


  164. XAYDALASOUK K, Strobel M, Buisson Y, Black AP, et al
    Seroprevalence and risk factors of hepatitis B and C virus infections in female workers of Lao garment factories.
    PLoS One. 2018;13:e0199919.
    PubMed     Text format     Abstract available


  165. XIONG QF, Xiong T, Huang P, Zhong YD, et al
    Early predictors of acute hepatitis B progression to liver failure.
    PLoS One. 2018;13:e0201049.
    PubMed     Text format     Abstract available


  166. SOOD A, Suryaprasad A, Trickey A, Kanchi S, et al
    The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey.
    PLoS One. 2018;13:e0200461.
    PubMed     Text format     Abstract available


  167. CUYPERS L, Perez AB, Chueca N, Aldamiz-Echevarria T, et al
    Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis.
    PLoS One. 2018;13:e0201268.
    PubMed     Text format     Abstract available


  168. EVANS H, Balasegaram S, Douthwaite S, Hunter L, et al
    An innovative approach to increase viral hepatitis diagnoses and linkage to care using opt-out testing and an integrated care pathway in a London Emergency Department.
    PLoS One. 2018;13:e0198520.
    PubMed     Text format     Abstract available


  169. MOTOYAMA H, Tamori A, Kubo S, Uchida-Kobayashi S, et al
    Correction: Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
    PLoS One. 2018;13:e0201423.
    PubMed     Text format     Abstract available


  170. TAT TRUNG N, Duong DC, Tong HV, Hien TTT, et al
    Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma.
    PLoS One. 2018;13:e0196081.
    PubMed     Text format     Abstract available


  171. EVON DM, Stewart PW, Amador J, Serper M, et al
    A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
    PLoS One. 2018;13:e0196908.
    PubMed     Text format     Abstract available


  172. NEESGAARD B, Ruhwald M, Krarup HB, Weis N, et al
    Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail.
    PLoS One. 2018;13:e0201629.
    PubMed     Text format     Abstract available


  173. JUN BG, Kim YD, Kim SG, Kim YS, et al
    Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study.
    PLoS One. 2018;13:e0201316.
    PubMed     Text format     Abstract available


  174. ELIZALDE MM, Perez PS, Sevic I, Grasso D, et al
    HBV subgenotypes F1b and F4 replication induces an incomplete autophagic process in hepatocytes: Role of BCP and preCore mutations.
    PLoS One. 2018;13:e0197109.
    PubMed     Text format     Abstract available


  175. MASSAQUOI TA, Burke RM, Yang G, Lakoh S, et al
    Cross sectional study of chronic hepatitis B prevalence among healthcare workers in an urban setting, Sierra Leone.
    PLoS One. 2018;13:e0201820.
    PubMed     Text format     Abstract available


  176. DU Z, Dong J, Bi J, Bai R, et al
    Predictive value of the preoperative neutrophil-to-lymphocyte ratio for the development of hepatocellular carcinoma in HBV-associated cirrhotic patients after splenectomy.
    PLoS One. 2018;13:e0195336.
    PubMed     Text format     Abstract available


  177. POSUWAN N, Vorayingyong A, Jaroonvanichkul V, Wasitthankasem R, et al
    Implementation of hepatitis B vaccine in high-risk young adults with waning immunity.
    PLoS One. 2018;13:e0202637.
    PubMed     Text format     Abstract available


  178. GOUNTAS I, Sypsa V, Blach S, Razavi H, et al
    HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era.
    PLoS One. 2018;13:e0202109.
    PubMed     Text format     Abstract available


  179. HSIEH YC, Jeng WJ, Huang CH, Teng W, et al
    Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
    PLoS One. 2018;13:e0202777.
    PubMed     Text format     Abstract available


  180. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Birth-cohort HCV screening target in Thailand to expand and optimize the national HCV screening for public health policy.
    PLoS One. 2018;13:e0202991.
    PubMed     Text format     Abstract available


  181. WHITMILL A, Kim S, Rojas V, Gulraiz F, et al
    Signature molecules expressed differentially in a liver disease stage-specific manner by HIV-1 and HCV co-infection.
    PLoS One. 2018;13:e0202524.
    PubMed     Text format     Abstract available


  182. AL MAHTAB M, Akbar SMF, Aguilar JC, Guillen G, et al
    Treatment of chronic hepatitis B naive patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).
    PLoS One. 2018;13:e0201236.
    PubMed     Text format     Abstract available


  183. GOYAL A, Romero-Severson EO
    Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil.
    PLoS One. 2018;13:e0203831.
    PubMed     Text format     Abstract available


  184. SILVA CMD, Peder LD, Guelere AM, Horvath JD, et al
    Seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-infected patients in an HBV endemic area in Brazil.
    PLoS One. 2018;13:e0203272.
    PubMed     Text format     Abstract available


  185. XING YF, Zhou DQ, He JS, Wei CS, et al
    Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV-DNA viral load and normal alanine aminotransferase level: A multicentre-based study in China.
    PLoS One. 2018;13:e0203220.
    PubMed     Text format     Abstract available


  186. WANG YW, Shen ZZ, Jiang Y
    Comparison of ARIMA and GM(1,1) models for prediction of hepatitis B in China.
    PLoS One. 2018;13:e0201987.
    PubMed     Text format     Abstract available


  187. OWUSU M, Bonney JK, Annan AA, Mawuli G, et al
    Aetiology of viral hepatitis among jaundiced patients presenting to a tertiary hospital in Ghana.
    PLoS One. 2018;13:e0203699.
    PubMed     Text format     Abstract available


  188. LUK KC, Coller KE, Dawson GJ, Cloherty GA, et al
    Identification of a putative novel genotype 3/rabbit hepatitis E virus (HEV) recombinant.
    PLoS One. 2018;13:e0203618.
    PubMed     Text format     Abstract available


  189. DAS S, Opoku J, Allston A, Kharfen M, et al
    Detecting spatial clusters of HIV and hepatitis coinfections.
    PLoS One. 2018;13:e0203674.
    PubMed     Text format     Abstract available


  190. KENNEDY K, Graham SM, Arora N, Shuhart MC, et al
    Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: Risk factors and age at diagnosis.
    PLoS One. 2018;13:e0204031.
    PubMed     Text format     Abstract available


  191. ZHANG XS, Iacono GL
    Estimating human-to-human transmissibility of hepatitis A virus in an outbreak at an elementary school in China, 2011.
    PLoS One. 2018;13:e0204201.
    PubMed     Text format     Abstract available


  192. VALENCIA LA ROSA J, Ryan P, Alvaro-Meca A, Troya J, et al
    HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination.
    PLoS One. 2018;13:e0204795.
    PubMed     Text format     Abstract available


  193. BOTTINO FO, Gardinali NR, Salvador SBS, Figueiredo AS, et al
    Cynomolgus monkeys (Macaca fascicularis) experimentally and naturally infected with hepatitis E virus: The bone marrow as a possible new viral target.
    PLoS One. 2018;13:e0205039.
    PubMed     Text format     Abstract available


  194. UCHIDA Y, Naiki K, Kouyama JI, Sugawara K, et al
    Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
    PLoS One. 2018;13:e0205600.
    PubMed     Text format     Abstract available


  195. SOSA-JURADO F, Melendez-Mena D, Rosas-Murrieta NH, Guzman-Flores B, et al
    Effectiveness of PCR primers for the detection of occult hepatitis B virus infection in Mexican patients.
    PLoS One. 2018;13:e0205356.
    PubMed     Text format     Abstract available


  196. DA SILVA EN, Baker A, Alshekaili J, Karpe K, et al
    A randomized trial of serological and cellular responses to hepatitis B vaccination in chronic kidney disease.
    PLoS One. 2018;13:e0204477.
    PubMed     Text format     Abstract available


  197. JUANBELTZ R, Martinez-Baz I, San Miguel R, Goni-Esarte S, et al
    Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients.
    PLoS One. 2018;13:e0205277.
    PubMed     Text format     Abstract available


  198. SCHNELL G, Krishnan P, Tripathi R, Beyer J, et al
    Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
    PLoS One. 2018;13:e0205186.
    PubMed     Text format     Abstract available


  199. FAHMY AM, Khabir M, Blanchet M, Labonte P, et al
    LC3B is not recruited along with the autophagy elongation complex (ATG5-12/16L1) at HCV replication site and is dispensable for viral replication.
    PLoS One. 2018;13:e0205189.
    PubMed     Text format     Abstract available


  200. TAKAHASHI A, Moriya K, Ohira H, Arinaga-Hino T, et al
    Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey.
    PLoS One. 2018;13:e0204772.
    PubMed     Text format     Abstract available


  201. MCCLURE MW, Berliba E, Tsertsvadze T, Streinu-Cercel A, et al
    Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.
    PLoS One. 2018;13:e0204974.
    PubMed     Text format     Abstract available


  202. NISBET AI, Omuse G, Revathi G, Adam RD, et al
    Seroprevalence data at a private teaching hospital in Kenya: An examination of Toxoplasma gondii, cytomegalovirus, rubella, hepatitis A, and Entamoeba histolytica.
    PLoS One. 2018;13:e0204867.
    PubMed     Text format     Abstract available


  203. MARTINEZ-RODRIGUEZ ML, Uribe-Noguez LA, Arroyo-Anduiza CI, Mata-Marin JA, et al
    Prevalence and risk factors of Occult Hepatitis C infections in blood donors from Mexico City.
    PLoS One. 2018;13:e0205659.
    PubMed     Text format     Abstract available


  204. SUIJKERBUIJK AWM, van Hoek AJ, Koopsen J, de Man RA, et al
    Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.
    PLoS One. 2018;13:e0207037.
    PubMed     Text format     Abstract available


  205. CHENG PN, Chiu HC, Chiu YC, Chen SC, et al
    Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community.
    PLoS One. 2018;13:e0206947.
    PubMed     Text format     Abstract available


  206. LIU C, Wang L, Xie H, Zhang L, et al
    The relationship between serum hepatitis B virus DNA level and liver histology in patients with chronic HBV infection.
    PLoS One. 2018;13:e0206060.
    PubMed     Text format     Abstract available


  207. JANG TY, Yeh ML, Huang CI, Lin ZY, et al
    Association of hyperuricemia with disease severity in chronic hepatitis C patients.
    PLoS One. 2018;13:e0207043.
    PubMed     Text format     Abstract available


  208. INOUE T, Ito Y, Nishizawa N, Eshima K, et al
    RAMP1 in Kupffer cells is a critical regulator in immune-mediated hepatitis.
    PLoS One. 2018;13:e0200432.
    PubMed     Text format     Abstract available


  209. KHAN B, Duncan I, Saad M, Schaefer D, et al
    Combination interventions for Hepatitis C and Cirrhosis reduction among people who inject drugs: An agent-based, networked population simulation experiment.
    PLoS One. 2018;13:e0206356.
    PubMed     Text format     Abstract available


  210. BUTI M, Dominguez-Hernandez R, Casado MA, Sabater E, et al
    Healthcare value of implementing hepatitis C screening in the adult general population in Spain.
    PLoS One. 2018;13:e0208036.
    PubMed     Text format     Abstract available


  211. CHOWDHURY P, Sahuc ME, Rouille Y, Riviere C, et al
    Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
    PLoS One. 2018;13:e0198226.
    PubMed     Text format     Abstract available


  212. RAJAMOORTHY Y, Radam A, Taib NM, Rahim KA, et al
    The relationship between perceptions and self-paid hepatitis B vaccination: A structural equation modeling approach.
    PLoS One. 2018;13:e0208402.
    PubMed     Text format     Abstract available


  213. RAU M, Schmitt J, Berg T, Kremer AE, et al
    Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients.
    PLoS One. 2018;13:e0208225.
    PubMed     Text format     Abstract available


  214. ABADIE R, Goldenberg S, Welch-Lazoritz M, Fisher CB, et al
    Establishing trust in HIV/HCV research among people who inject drugs (PWID): Insights from empirical research.
    PLoS One. 2018;13:e0208410.
    PubMed     Text format     Abstract available


  215. BOUACIDA L, Suin V, Hutse V, Boudewijns M, et al
    Distribution of HCV genotypes in Belgium from 2008 to 2015.
    PLoS One. 2018;13:e0207584.
    PubMed     Text format     Abstract available


  216. JUANBELTZ R, Perez-Garcia A, Aguinaga A, Martinez-Baz I, et al
    Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain.
    PLoS One. 2018;13:e0208554.
    PubMed     Text format     Abstract available


  217. MADDEN A, Hopwood M, Neale J, Treloar C, et al
    Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
    PLoS One. 2018;13:e0207226.
    PubMed     Text format     Abstract available


  218. LAWRENCE YA, Dangott LJ, Rodrigues-Hoffmann A, Steiner JM, et al
    Proteomic analysis of liver tissue from dogs with chronic hepatitis.
    PLoS One. 2018;13:e0208394.
    PubMed     Text format     Abstract available


  219. BADAWI A, Di Giuseppe G, Arora P
    Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007-2017).
    PLoS One. 2018;13:e0208839.
    PubMed     Text format     Abstract available


  220. DIMEGLIO C, Beau F, Broult J, Gouy P, et al
    Hepatitis E prevalence in French Polynesian blood donors.
    PLoS One. 2018;13:e0208934.
    PubMed     Text format     Abstract available


  221. GUALERZI A, Bellan M, Smirne C, Tran Minh M, et al
    Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents.
    PLoS One. 2018;13:e0209216.
    PubMed     Text format     Abstract available


  222. PARK H, Jeong D, Nguyen P, Henry L, et al
    Correction: Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis.
    PLoS One. 2018;13:e0209715.
    PubMed     Text format     Abstract available


  223. GALLACH M, Vergara M, da Costa JP, Miquel M, et al
    Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.
    PLoS One. 2018;13:e0208112.
    PubMed     Text format     Abstract available


  224. BILLA O, Chalouni M, Salmon D, Poizot-Martin I, et al
    Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort.
    PLoS One. 2018;13:e0208657.
    PubMed     Text format     Abstract available


  225. ALBERTS CJ, Schim van der Loeff MF, Sadik S, Zuure FR, et al
    Hepatitis E virus seroprevalence and determinants in various study populations in the Netherlands.
    PLoS One. 2018;13:e0208522.
    PubMed     Text format     Abstract available


  226. PAPIC N, Zidovec Lepej S, Gorenec L, Grgic I, et al
    The association of semaphorins 3C, 5A and 6D with liver fibrosis stage in chronic hepatitis C.
    PLoS One. 2018;13:e0209481.
    PubMed     Text format     Abstract available


  227. KAWAGISHI N, Suda G, Nakamura A, Kimura M, et al
    Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
    PLoS One. 2018;13:e0209615.
    PubMed     Text format     Abstract available


  228. LIU CH, Liu CJ, Su TH, Yang HC, et al
    Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan.
    PLoS One. 2018;13:e0209299.
    PubMed     Text format     Abstract available


  229. ABE K, Takahashi A, Fujita M, Imaizumi H, et al
    Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease.
    PLoS One. 2018;13:e0198757.
    PubMed     Text format     Abstract available


  230. MATSUMOTO K, Wu Y, Kitazawa T, Fujita S, et al
    Cost of illness of hepatocellular carcinoma in Japan: A time trend and future projections.
    PLoS One. 2018;13:e0199188.
    PubMed     Text format     Abstract available


  231. MULLHAUPT B, Bruggmann P, Bihl F, Blach S, et al
    Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
    PLoS One. 2018;13:e0209374.
    PubMed     Text format     Abstract available


  232. KAKIZAKI M, Yamamoto Y, Yabuta S, Kurosaki N, et al
    The immunological function of extracellular vesicles in hepatitis B virus-infected hepatocytes.
    PLoS One. 2018;13:e0205886.
    PubMed     Text format     Abstract available


  233. SPENGLER JR, McElroy AK, Harmon JR, Coleman-McCray JD, et al
    Human immune cell engraftment does not alter development of severe acute Rift Valley fever in mice.
    PLoS One. 2018;13:e0201104.
    PubMed     Text format     Abstract available


  234. MERIKI HD, Tufon KA, Anong DN, Tony NJ, et al
    Vaccine uptake and immune responses to HBV infection amongst vaccinated and non-vaccinated healthcare workers, household and sexual contacts to chronically infected HBV individuals in the South West Region of Cameroon.
    PLoS One. 2018;13:e0200157.
    PubMed     Text format     Abstract available


  235. MANGIA A, Losappio R, Cenderello G, Potenza D, et al
    Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
    PLoS One. 2018;13:e0200568.
    PubMed     Text format     Abstract available


  236. ABEL S, Cuzin L, Da Cunha S, Bolivard JM, et al
    Reaching the WHO target of testing persons in jails in prisons will need diverse efforts and resources.
    PLoS One. 2018;13:e0202985.
    PubMed     Text format     Abstract available


  237. TUFON KA, Anong DN, Meriki HD, Georges TD, et al
    Characterization and assessment of HBV chronically infected patients: Identification of those eligible for treatment in the South West region of Cameroon.
    PLoS One. 2018;13:e0203312.
    PubMed     Text format     Abstract available


  238. VALERIAN DM, Mauka WI, Kajeguka DC, Mgabo M, et al
    Prevalence and causes of blood donor deferrals among clients presenting for blood donation in northern Tanzania.
    PLoS One. 2018;13:e0206487.
    PubMed     Text format     Abstract available


  239. DAVIS SM, Davidov D, Kristjansson AL, Zullig K, et al
    Qualitative case study of needle exchange programs in the Central Appalachian region of the United States.
    PLoS One. 2018;13:e0205466.
    PubMed     Text format     Abstract available


  240. BARANYI A, Meinitzer A, Rothenhausler HB, Amouzadeh-Ghadikolai O, et al
    Metabolomics approach in the investigation of depression biomarkers in pharmacologically induced immune-related depression.
    PLoS One. 2018;13:e0208238.
    PubMed     Text format     Abstract available


  241. WERNER RN, Gaskins M, Nast A, Dressler C, et al
    Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection - A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis.
    PLoS One. 2018;13:e0208107.
    PubMed     Text format     Abstract available


  242. CORREA ASM, Lamarao LM, Vieira PCM, de Castro RBH, et al
    Prevalence, incidence and residual risk of transfusion-transmitted HBV infection before and after the implementation of HBV-NAT in northern Brazil.
    PLoS One. 2018;13:e0208414.
    PubMed     Text format     Abstract available


    January 2017
  243. COUTO I, Victoria M, Veloso VG, Rodrigues L, et al
    Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection.
    PLoS One. 2017;12:e0174453.
    PubMed     Text format     Abstract available


  244. GARDINALI NR, Guimaraes JR, Melgaco JG, Kevorkian YB, et al
    Cynomolgus monkeys are successfully and persistently infected with hepatitis E virus genotype 3 (HEV-3) after long-term immunosuppressive therapy.
    PLoS One. 2017;12:e0174070.
    PubMed     Text format     Abstract available


  245. YOSHIOKA T, Tatsumi T, Miyagi T, Mukai K, et al
    Frequency and role of NKp46 and NKG2A in hepatitis B virus infection.
    PLoS One. 2017;12:e0174103.
    PubMed     Text format     Abstract available


  246. RALLON N, Garcia M, Garcia-Samaniego J, Rodriguez N, et al
    HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells.
    PLoS One. 2017;12:e0173943.
    PubMed     Text format     Abstract available


  247. GUPTA N, Kabahizi J, Mukabatsinda C, Walker TD, et al
    "Waiting for DAAs": A retrospective chart review of patients with untreated hepatitis C in Rwanda.
    PLoS One. 2017;12:e0174148.
    PubMed     Text format     Abstract available


  248. GUINOISEAU T, Moreau A, Hohnadel G, Ngo-Giang-Huong N, et al
    Deep sequencing is an appropriate tool for the selection of unique Hepatitis C virus (HCV) variants after single genomic amplification.
    PLoS One. 2017;12:e0174852.
    PubMed     Text format     Abstract available


  249. HUANG YJ, Chang CS, Peng YC, Yeh HZ, et al
    On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B.
    PLoS One. 2017;12:e0174046.
    PubMed     Text format     Abstract available


  250. LOWE PP, Gyongyosi B, Satishchandran A, Iracheta-Vellve A, et al
    Alcohol-related changes in the intestinal microbiome influence neutrophil infiltration, inflammation and steatosis in early alcoholic hepatitis in mice.
    PLoS One. 2017;12:e0174544.
    PubMed     Text format     Abstract available


  251. CHEN HC, Chung CH, Wang CH, Lin JC, et al
    Increased risk of sudden sensorineural hearing loss in patients with hepatitis virus infection.
    PLoS One. 2017;12:e0175266.
    PubMed     Text format     Abstract available


  252. YE Q, Yin W, Zhang L, Xiao H, et al
    The value of grip test, lysophosphatidlycholines, glycerophosphocholine, ornithine, glucuronic acid decrement in assessment of nutritional and metabolic characteristics in hepatitis B cirrhosis.
    PLoS One. 2017;12:e0175165.
    PubMed     Text format     Abstract available


  253. KACZMAREK DJ, Kokordelis P, Kramer B, Glassner A, et al
    Alterations of the NK cell pool in HIV/HCV co-infection.
    PLoS One. 2017;12:e0174465.
    PubMed     Text format     Abstract available


  254. CHEN H, Chen L
    Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.
    PLoS One. 2017;12:e0175189.
    PubMed     Text format     Abstract available


  255. KOMOLMIT P, Charoensuk K, Thanapirom K, Suksawatamnuay S, et al
    Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial.
    PLoS One. 2017;12:e0174608.
    PubMed     Text format     Abstract available


  256. FERNANDEZ-CABALLERO JA, Alvarez M, Chueca N, Perez AB, et al
    The cobas(R) HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice.
    PLoS One. 2017;12:e0175564.
    PubMed     Text format     Abstract available


  257. YANG CM, Yoon JC, Park JH, Lee JM, et al
    Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.
    PLoS One. 2017;12:e0175793.
    PubMed     Text format     Abstract available


  258. CHLIBEK R, Smetana J, Sosovickova R, Gal P, et al
    Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening.
    PLoS One. 2017;12:e0175525.
    PubMed     Text format     Abstract available


  259. NGUYEN HM, Sy BT, Trung NT, Hoan NX, et al
    Prevalence and genotype distribution of hepatitis delta virus among chronic hepatitis B carriers in Central Vietnam.
    PLoS One. 2017;12:e0175304.
    PubMed     Text format     Abstract available


  260. DU H, Yang J, Bai J, Ming K, et al
    A flavone-polysaccharide based prescription attenuates the mitochondrial dysfunction induced by duck hepatitis A virus type 1.
    PLoS One. 2017;12:e0175495.
    PubMed     Text format     Abstract available


  261. LE GUILLOU-GUILLEMETTE H, Pivert A, Bouthry E, Henquell C, et al
    Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma.
    PLoS One. 2017;12:e0174651.
    PubMed     Text format     Abstract available


  262. FAN Z, EnQiang C, Yao DL, LiBo Y, et al
    Neutrophil-lymphocyte ratio predicts short term mortality in patients with hepatitis B virus-related acute-on-chronic liver failure treated with an artificial liver support system.
    PLoS One. 2017;12:e0175332.
    PubMed     Text format     Abstract available


  263. NEFFATTI H, Lebraud P, Hottelet C, Gharbi J, et al
    Southern Tunisia: A still high endemicity area for hepatitis A.
    PLoS One. 2017;12:e0175887.
    PubMed     Text format     Abstract available


  264. XU E, Cao H, Lin L, Liu H, et al
    rs10499194 polymorphism in the tumor necrosis factor-alpha inducible protein 3 (TNFAIP3) gene is associated with type-1 autoimmune hepatitis risk in Chinese Han population.
    PLoS One. 2017;12:e0176471.
    PubMed     Text format     Abstract available


  265. CAPILENO YA, Van den Bergh R, Donchunk D, Hinderaker SG, et al
    Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan.
    PLoS One. 2017;12:e0175562.
    PubMed     Text format     Abstract available


  266. SLOT E, Zaaijer HL, Molier M, Van den Hurk K, et al
    Meat consumption is a major risk factor for hepatitis E virus infection.
    PLoS One. 2017;12:e0176414.
    PubMed     Text format     Abstract available


  267. PENE V, Lemasson M, Harper F, Pierron G, et al
    Role of cleavage at the core-E1 junction of hepatitis C virus polyprotein in viral morphogenesis.
    PLoS One. 2017;12:e0175810.
    PubMed     Text format     Abstract available


  268. JEONG H, Baek SY, Kim SW, Eun YH, et al
    Comorbidities of rheumatoid arthritis: Results from the Korean National Health and Nutrition Examination Survey.
    PLoS One. 2017;12:e0176260.
    PubMed     Text format     Abstract available


  269. FRIAS M, Rivero-Juarez A, Tellez F, Perez-Perez M, et al
    Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy.
    PLoS One. 2017;12:e0177141.
    PubMed     Text format     Abstract available


  270. GENCAY M, Hubner K, Gohl P, Seffner A, et al
    Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population.
    PLoS One. 2017;12:e0172101.
    PubMed     Text format     Abstract available


  271. MOQUEET N, Kanagaratham C, Gill MJ, Hull M, et al
    A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection.
    PLoS One. 2017;12:e0176282.
    PubMed     Text format     Abstract available


  272. DIRKSEN K, Spee B, Penning LC, van den Ingh TSGAM, et al
    Gene expression patterns in the progression of canine copper-associated chronic hepatitis.
    PLoS One. 2017;12:e0176826.
    PubMed     Text format     Abstract available


  273. SUN J, Robinson L, Lee NL, Welles S, et al
    No contribution of lifestyle and environmental exposures to gender discrepancy of liver disease severity in chronic hepatitis b infection: Observations from the Haimen City cohort.
    PLoS One. 2017;12:e0175482.
    PubMed     Text format     Abstract available


  274. BIRGER RB, Le T, Kouyos RD, Grenfell BT, et al
    The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam.
    PLoS One. 2017;12:e0177195.
    PubMed     Text format     Abstract available


  275. PANDOLFI R, Ramos de Almeida D, Alves Pinto M, Kreutz LC, et al
    In house ELISA based on recombinant ORF2 protein underline high prevalence of IgG anti-hepatitis E virus amongst blood donors in south Brazil.
    PLoS One. 2017;12:e0176409.
    PubMed     Text format     Abstract available


  276. CHANG CC, Hsu HJ, Yen JH, Lo SY, et al
    A Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81.
    PLoS One. 2017;12:e0177383.
    PubMed     Text format     Abstract available


  277. NAKAMURA M, Kanda T, Jiang X, Haga Y, et al
    Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis.
    PLoS One. 2017;12:e0177302.
    PubMed     Text format     Abstract available


  278. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence.
    PLoS One. 2017;12:e0177022.
    PubMed     Text format     Abstract available


  279. BAEZ PA, Lopez MC, Duque-Jaramillo A, Pelaez D, et al
    First evidence of the Hepatitis E virus in environmental waters in Colombia.
    PLoS One. 2017;12:e0177525.
    PubMed     Text format     Abstract available


  280. D'ARMINIO MONFORTE A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, et al
    Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.
    PLoS One. 2017;12:e0177402.
    PubMed     Text format     Abstract available


  281. AGGARWAL R, Chen Q, Goel A, Seguy N, et al
    Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.
    PLoS One. 2017;12:e0176503.
    PubMed     Text format     Abstract available


  282. CENTO V, Nguyen THT, Di Carlo D, Biliotti E, et al
    Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
    PLoS One. 2017;12:e0177352.
    PubMed     Text format     Abstract available


  283. ECKHARDT B, Winkelstein ER, Shu MA, Carden MR, et al
    Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention.
    PLoS One. 2017;12:e0177341.
    PubMed     Text format     Abstract available


  284. JANG Y, Kim JH, Lee K
    Validation of the revised piper fatigue scale in Koreans with chronic hepatitis B.
    PLoS One. 2017;12:e0177690.
    PubMed     Text format     Abstract available


  285. HAN Z, Yin Y, Zhang Y, Ehrhardt S, et al
    Knowledge of and attitudes towards hepatitis B and its transmission from mother to child among pregnant women in Guangdong Province, China.
    PLoS One. 2017;12:e0178671.
    PubMed     Text format     Abstract available


  286. HUNDIE GB, Raj VS, GebreMichael D, Pas SD, et al
    Genetic diversity of hepatitis C virus in Ethiopia.
    PLoS One. 2017;12:e0179064.
    PubMed     Text format     Abstract available


  287. LOWE PP, Gyongyosi B, Satishchandran A, Iracheta-Vellve A, et al
    Correction: Alcohol-related changes in the intestinal microbiome influence neutrophil infiltration, inflammation and steatosis in early alcoholic hepatitis in mice.
    PLoS One. 2017;12:e0179070.
    PubMed     Text format     Abstract available


  288. ZHENG H, Zou AE, Saad MA, Wang XQ, et al
    Alcohol-dysregulated microRNAs in hepatitis B virus-related hepatocellular carcinoma.
    PLoS One. 2017;12:e0178547.
    PubMed     Text format     Abstract available


  289. NAIK AS, Owsianka A, Palmer BA, O'Halloran CJ, et al
    Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus.
    PLoS One. 2017;12:e0175349.
    PubMed     Text format     Abstract available


  290. EL HADAD S, Al-Hamdan H, Linjawi S
    Partial sequencing analysis of the NS5B region confirmed the predominance of hepatitis C virus genotype 1 infection in Jeddah, Saudi Arabia.
    PLoS One. 2017;12:e0178225.
    PubMed     Text format     Abstract available


  291. JANG TY, Lin PC, Huang CI, Liao YM, et al
    Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients.
    PLoS One. 2017;12:e0178883.
    PubMed     Text format     Abstract available


  292. TAUBERT R, Hardtke-Wolenski M, Noyan F, Lalanne C, et al
    Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis.
    PLoS One. 2017;12:e0179074.
    PubMed     Text format     Abstract available


  293. CHIU NC, Su CW, Liu CA, Huang YH, et al
    Interval to vascularization development in cirrhotic precursor nodules in patients with hepatitis B and C virus co-infections.
    PLoS One. 2017;12:e0178841.
    PubMed     Text format     Abstract available


  294. SAHA D, Pal A, Sarkar N, Das D, et al
    Occult hepatitis B virus infection in HIV positive patients at a tertiary healthcare unit in eastern India.
    PLoS One. 2017;12:e0179035.
    PubMed     Text format     Abstract available


  295. HARRIS BJ, Holzmayer V, Qureshi H, Khan MA, et al
    Hepatitis B genotypes and surface antigen mutants present in Pakistani blood donors.
    PLoS One. 2017;12:e0178988.
    PubMed     Text format     Abstract available


  296. ALVARO-MECA A, Berenguer J, Diaz A, Micheloud D, et al
    Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era.
    PLoS One. 2017;12:e0179493.
    PubMed     Text format     Abstract available


  297. CHU PS, Nakamoto N, Taniki N, Ojiro K, et al
    On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C.
    PLoS One. 2017;12:e0179096.
    PubMed     Text format     Abstract available


  298. NDOW G, Gore ML, Shimakawa Y, Suso P, et al
    Hepatitis B testing and treatment in HIV patients in The Gambia-Compliance with international guidelines and clinical outcomes.
    PLoS One. 2017;12:e0179025.
    PubMed     Text format     Abstract available


  299. LEE JW, Kim W, Kwon EK, Kim Y, et al
    Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.
    PLoS One. 2017;12:e0179094.
    PubMed     Text format     Abstract available


  300. CHENG ST, Tang H, Ren JH, Chen X, et al
    Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo.
    PLoS One. 2017;12:e0179605.
    PubMed     Text format     Abstract available


  301. OU X, Mao S, Cao J, Cheng A, et al
    Comparative analysis of virus-host interactions caused by a virulent and an attenuated duck hepatitis A virus genotype 1.
    PLoS One. 2017;12:e0178993.
    PubMed     Text format     Abstract available


  302. WU YT, Li X, Liu ZL, Xu Z, et al
    Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0179680.
    PubMed     Text format     Abstract available


  303. CAPILENO YA, Van den Bergh R, Donchuk D, Hinderaker SG, et al
    Correction: Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan.
    PLoS One. 2017;12:e0180286.
    PubMed     Text format     Abstract available


  304. MASCIA C, Vita S, Zuccala P, Marocco R, et al
    Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.
    PLoS One. 2017;12:e0179400.
    PubMed     Text format     Abstract available


  305. ELSHERIF O, Bannan C, Keating S, McKiernan S, et al
    Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response.
    PLoS One. 2017;12:e0178398.
    PubMed     Text format     Abstract available


  306. GUILLOT C, Martel N, Berby F, Bordes I, et al
    Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes.
    PLoS One. 2017;12:e0179697.
    PubMed     Text format     Abstract available


  307. LIN HC, Xirasagar S, Lee HC, Huang CC, et al
    Association of Alzhemier's disease with hepatitis C among patients with bipolar disorder.
    PLoS One. 2017;12:e0179312.
    PubMed     Text format     Abstract available


  308. LIU Z, Li S, Liu Y, Guo W, et al
    PD1 is highly expressed in diffuse large B-cell lymphoma with hepatitis B virus infection.
    PLoS One. 2017;12:e0180390.
    PubMed     Text format     Abstract available


  309. ISHIZAKI A, Tran VT, Nguyen CH, Tanimoto T, et al
    Discrepancies in prevalence trends for HIV, hepatitis B virus, and hepatitis C virus in Haiphong, Vietnam from 2007 to 2012.
    PLoS One. 2017;12:e0179616.
    PubMed     Text format     Abstract available


  310. LIU T, Wang F, Zhang S, Wang F, et al
    Whole-gene analysis of two groups of hepatitis B virus C/D inter-genotype recombinant strains isolated in Tibet, China.
    PLoS One. 2017;12:e0179846.
    PubMed     Text format     Abstract available


  311. BELAUNZARAN-ZAMUDIO PF, Mosqueda-Gomez JL, Macias-Hernandez A, Sierra-Madero JG, et al
    Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico.
    PLoS One. 2017;12:e0179931.
    PubMed     Text format     Abstract available


  312. ABEBE M, Ali I, Ayele S, Overbo J, et al
    Seroprevalence and risk factors of Hepatitis E Virus infection among pregnant women in Addis Ababa, Ethiopia.
    PLoS One. 2017;12:e0180078.
    PubMed     Text format     Abstract available


  313. SHIU TY, Huang SM, Shih YL, Chu HC, et al
    Correction: Hepatitis C Virus Core Protein Down-Regulates p21Waf1/Cip1 and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells.
    PLoS One. 2017;12:e0181299.
    PubMed     Text format     Abstract available


  314. SNOW KJ, Richards AH, Kinner SA
    Use of multiple data sources to estimate hepatitis C seroprevalence among prisoners: A retrospective cohort study.
    PLoS One. 2017;12:e0180646.
    PubMed     Text format     Abstract available


  315. RENDON JC, Cortes-Mancera F, Restrepo-Gutierrez JC, Hoyos S, et al
    Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia.
    PLoS One. 2017;12:e0180447.
    PubMed     Text format     Abstract available


  316. LEVENTER-ROBERTS M, Hammerman A, Brufman I, Hoshen M, et al
    Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.
    PLoS One. 2017;12:e0176858.
    PubMed     Text format     Abstract available


  317. JANG YR, Shin Y, Jin CE, Koo B, et al
    Molecular detection of Coxiella burnetii from the formalin-fixed tissues of Q fever patients with acute hepatitis.
    PLoS One. 2017;12:e0180237.
    PubMed     Text format     Abstract available


  318. LOPEZ-RODRIGUEZ R, Hernandez-Bartolome A, Borque MJ, Rodriguez-Munoz Y, et al
    Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C.
    PLoS One. 2017;12:e0180927.
    PubMed     Text format     Abstract available


  319. DALGARD O, Weiland O, Noraberg G, Karlsen L, et al
    Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    PLoS One. 2017;12:e0179764.
    PubMed     Text format     Abstract available


  320. DIESTELHORST J, Junge N, Schlue J, Falk CS, et al
    Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy.
    PLoS One. 2017;12:e0181107.
    PubMed     Text format     Abstract available


  321. ANDRE-GARNIER E, Besse B, Rodallec A, Ribeyrol O, et al
    An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains.
    PLoS One. 2017;12:e0179562.
    PubMed     Text format     Abstract available


  322. NEUKAM K, Martinez AP, Culasso ACA, Ridruejo E, et al
    NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b.
    PLoS One. 2017;12:e0182193.
    PubMed     Text format     Abstract available


  323. MATSUO J, Do SH, Yamamoto C, Nagashima S, et al
    Clustering infection of hepatitis B virus genotype B4 among residents in Vietnam, and its genomic characters both intra- and extra-family.
    PLoS One. 2017;12:e0177248.
    PubMed     Text format     Abstract available


  324. RUSSELLI G, Pizzillo P, Iannolo G, Barbera F, et al
    HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation.
    PLoS One. 2017;12:e0181683.
    PubMed     Text format     Abstract available


  325. SABET S, George MA, El-Shorbagy HM, Bassiony H, et al
    Gelatin nanoparticles enhance delivery of hepatitis C virus recombinant NS2 gene.
    PLoS One. 2017;12:e0181723.
    PubMed     Text format     Abstract available


  326. MERDAN M, Bekiryazici Z, Kesemen T, Khaniyev T, et al
    Deterministic stability and random behavior of a Hepatitis C model.
    PLoS One. 2017;12:e0181571.
    PubMed     Text format     Abstract available


  327. STELZL E, Haas B, Bauer B, Zhang S, et al
    First identification of a recombinant form of hepatitis C virus in Austrian patients by full-genome next generation sequencing.
    PLoS One. 2017;12:e0181273.
    PubMed     Text format     Abstract available


  328. CHOTUN N, Preiser W, van Rensburg CJ, Fernandez P, et al
    Point-of-care screening for hepatitis B virus infection in pregnant women at an antenatal clinic: A South African experience.
    PLoS One. 2017;12:e0181267.
    PubMed     Text format     Abstract available


  329. TAN WG, Zubkova I, Kachko A, Wells F, et al
    Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.
    PLoS One. 2017;12:e0181578.
    PubMed     Text format     Abstract available


  330. HUGHES MG JR, Tucker WW, Reddy S, Brier ME, et al
    Rate of hepatitis C viral clearance by human livers in human patients: Liver transplantation modeling primary infection and implications for studying entry inhibition.
    PLoS One. 2017;12:e0180719.
    PubMed     Text format     Abstract available


  331. KIM BH, Choi HY, Ki M, Kim KA, et al
    Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea.
    PLoS One. 2017;12:e0182391.
    PubMed     Text format     Abstract available


  332. GOUVEIA LR, Santos JC, Silva RD, Batista AD, et al
    Diagnosis of coinfection by schistosomiasis and viral hepatitis B or C using 1H NMR-based metabonomics.
    PLoS One. 2017;12:e0182196.
    PubMed     Text format     Abstract available


  333. SAGNELLI C, Uberti-Foppa C, Hasson H, Bellini G, et al
    Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients.
    PLoS One. 2017;12:e0181890.
    PubMed     Text format     Abstract available


  334. NAGAOKI Y, Imamura M, Aikata H, Daijo K, et al
    The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
    PLoS One. 2017;12:e0182710.
    PubMed     Text format     Abstract available


  335. KIM YA, Trinh S, Thura S, Kyi KP, et al
    Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar.
    PLoS One. 2017;12:e0181603.
    PubMed     Text format     Abstract available


  336. HUANG CM, Chang KC, Hung CH, Chiu KW, et al
    Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C.
    PLoS One. 2017;12:e0182204.
    PubMed     Text format     Abstract available


  337. WISSKIRCHEN K, Metzger K, Schreiber S, Asen T, et al
    Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use.
    PLoS One. 2017;12:e0182936.
    PubMed     Text format     Abstract available


  338. GOSSELIN A, Lelievre E, Ravalihasy A, Lydie N, et al
    "Times Are Changing": The Impact of HIV Diagnosis on Sub-Saharan Migrants' Lives in France.
    PLoS One. 2017;12:e0170226.
    PubMed     Text format     Abstract available


  339. WU CK, Liang CM, Hsu CN, Hung TH, et al
    The Role of Adjuvant Acid Suppression on the Outcomes of Bleeding Esophageal Varices after Endoscopic Variceal Ligation.
    PLoS One. 2017;12:e0169884.
    PubMed     Text format     Abstract available


  340. NIU C, Livingston CM, Li L, Beran RK, et al
    The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection.
    PLoS One. 2017;12:e0169648.
    PubMed     Text format     Abstract available


  341. LIU X, He L, Han J, Wang L, et al
    Association of neutrophil-lymphocyte ratio and T lymphocytes with the pathogenesis and progression of HBV-associated primary liver cancer.
    PLoS One. 2017;12:e0170605.
    PubMed     Text format     Abstract available


  342. CHO YE, Im EJ, Moon PG, Mezey E, et al
    Increased liver-specific proteins in circulating extracellular vesicles as potential biomarkers for drug- and alcohol-induced liver injury.
    PLoS One. 2017;12:e0172463.
    PubMed     Text format     Abstract available


  343. DE WEGGHELEIRE A, An S, De Baetselier I, Soeung P, et al
    A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening.
    PLoS One. 2017;12:e0183530.
    PubMed     Text format     Abstract available


  344. BUTT ZA, Shrestha N, Wong S, Kuo M, et al
    A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia.
    PLoS One. 2017;12:e0183609.
    PubMed     Text format     Abstract available


  345. GUO G, Zhang L, Ye S, Hu Y, et al
    Polymorphisms and features of cytomegalovirus UL144 and UL146 in congenitally infected neonates with hepatic involvement.
    PLoS One. 2017;12:e0171959.
    PubMed     Text format     Abstract available


  346. CARRIERI MP, Marcellin F, Fressard L, Preau M, et al
    Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey).
    PLoS One. 2017;12:e0171645.
    PubMed     Text format     Abstract available


  347. MANICKAM C, Wachtman L, Martinot AJ, Giavedoni LD, et al
    Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus).
    PLoS One. 2017;12:e0170240.
    PubMed     Text format     Abstract available


  348. MORSICA G, Bagaglio S, Spagnuolo V, Castagna A, et al
    Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study.
    PLoS One. 2017;12:e0184128.
    PubMed     Text format     Abstract available


  349. SHIER MK, Iles JC, El-Wetidy MS, Ali HH, et al
    Molecular characterization and epidemic history of hepatitis C virus using core sequences of isolates from Central Province, Saudi Arabia.
    PLoS One. 2017;12:e0184163.
    PubMed     Text format     Abstract available


  350. HERMETET C, Dubois F, Gaudy-Graffin C, Bacq Y, et al
    Continuum of hepatitis C care in France: A 20-year cohort study.
    PLoS One. 2017;12:e0183232.
    PubMed     Text format     Abstract available


  351. KJAERGAARD M, Thiele M, Jansen C, Staehr Madsen B, et al
    High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal.
    PLoS One. 2017;12:e0173992.
    PubMed     Text format     Abstract available


  352. GARBA RM, Gadanya MA
    The role of intervention mapping in designing disease prevention interventions: A systematic review of the literature.
    PLoS One. 2017;12:e0174438.
    PubMed     Text format     Abstract available


  353. ZHENG Z, Sze CW, Keng CT, Al-Haddawi M, et al
    Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model.
    PLoS One. 2017;12:e0184127.
    PubMed     Text format     Abstract available


  354. DAVIES J, Li SQ, Tong SY, Baird RW, et al
    Establishing contemporary trends in hepatitis B sero-epidemiology in an Indigenous population.
    PLoS One. 2017;12:e0184082.
    PubMed     Text format     Abstract available


  355. GOMEZ-MORENO AZ, Pineda-Tenor D, Jimenez-Sousa MA, Sanchez-Ruano JJ, et al
    Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study.
    PLoS One. 2017;12:e0184404.
    PubMed     Text format     Abstract available


  356. VUTIEN P, Jin M, Le MH, Nguyen P, et al
    Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis.
    PLoS One. 2017;12:e0183851.
    PubMed     Text format     Abstract available


  357. WANG L, Cao M, Wei QL, Zhao ZH, et al
    A new model mimicking persistent HBV e antigen-negative infection using covalently closed circular DNA in immunocompetent mice.
    PLoS One. 2017;12:e0175992.
    PubMed     Text format     Abstract available


  358. GONZALEZ R, De la Rosa AJ, Rufini A, Rodriguez-Hernandez MA, et al
    Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation.
    PLoS One. 2017;12:e0174326.
    PubMed     Text format     Abstract available


  359. KEATING SM, Dodge JL, Norris PJ, Heitman J, et al
    The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study.
    PLoS One. 2017;12:e0181004.
    PubMed     Text format     Abstract available


  360. BUTI M, Manzano ML, Morillas RM, Garcia-Retortillo M, et al
    Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.
    PLoS One. 2017;12:e0184550.
    PubMed     Text format     Abstract available


  361. TUDESQ JJ, Dunyach-Remy C, Combescure C, Doncesco R, et al
    Microbial translocation is correlated with HIV evolution in HIV-HCV co-infected patients.
    PLoS One. 2017;12:e0183372.
    PubMed     Text format     Abstract available


  362. ROSINSKA M, Parda N, Kolakowska A, Godzik P, et al
    Factors associated with hepatitis C prevalence differ by the stage of liver fibrosis: A cross-sectional study in the general population in Poland, 2012-2016.
    PLoS One. 2017;12:e0185055.
    PubMed     Text format     Abstract available


  363. UITTE DE WILLIGE S, Keane FM, Bowen DG, Malfliet JJMC, et al
    Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease.
    PLoS One. 2017;12:e0178987.
    PubMed     Text format     Abstract available


  364. KRAUSKOPF J, de Kok TM, Schomaker SJ, Gosink M, et al
    Serum microRNA signatures as "liquid biopsies" for interrogating hepatotoxic mechanisms and liver pathogenesis in human.
    PLoS One. 2017;12:e0177928.
    PubMed     Text format     Abstract available


  365. WANG H, Zhang W, Gu H, Chen W, et al
    Identification and characterization of two linear epitope motifs in hepatitis E virus ORF2 protein.
    PLoS One. 2017;12:e0184947.
    PubMed     Text format     Abstract available


  366. HOU J, Brouwer WP, Kreefft K, Gama L, et al
    Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection.
    PLoS One. 2017;12:e0179920.
    PubMed     Text format     Abstract available


  367. GONZALES-GUSTAVSON E, Timoneda N, Fernandez-Cassi X, Caballero A, et al
    Identification of sapovirus GV.2, astrovirus VA3 and novel anelloviruses in serum from patients with acute hepatitis of unknown aetiology.
    PLoS One. 2017;12:e0185911.
    PubMed     Text format     Abstract available


  368. NAGATY A, Abd El-Wahab EW
    Real-life results of sofosbuvir based therapy in chronic hepatitis C -naive and -experienced patients in Egypt.
    PLoS One. 2017;12:e0184654.
    PubMed     Text format     Abstract available


  369. NOSAKA T, Naito T, Hiramatsu K, Ohtani M, et al
    Gene expression profiling of hepatocarcinogenesis in a mouse model of chronic hepatitis B.
    PLoS One. 2017;12:e0185442.
    PubMed     Text format     Abstract available


  370. YANG CK, Wang XK, Liao XW, Han CY, et al
    Aldehyde dehydrogenase 1 (ALDH1) isoform expression and potential clinical implications in hepatocellular carcinoma.
    PLoS One. 2017;12:e0182208.
    PubMed     Text format     Abstract available


  371. BIADGO B, Shiferaw E, Woldu B, Alene KA, et al
    Transfusion-transmissible viral infections among blood donors at the North Gondar district blood bank, northwest Ethiopia: A three year retrospective study.
    PLoS One. 2017;12:e0180416.
    PubMed     Text format     Abstract available


  372. PARASCHIV S, Banica L, Nicolae I, Niculescu I, et al
    Epidemic dispersion of HIV and HCV in a population of co-infected Romanian injecting drug users.
    PLoS One. 2017;12:e0185866.
    PubMed     Text format     Abstract available


  373. JARAMILLO CM, de La Hoz F, Porras A, di Filippo D, et al
    Characterization of hepatitis B virus in Amerindian children and mothers from Amazonas State, Colombia.
    PLoS One. 2017;12:e0181643.
    PubMed     Text format     Abstract available


  374. CHAMBAL LM, Samo Gudo E, Carimo A, Corte Real R, et al
    HBV infection in untreated HIV-infected adults in Maputo, Mozambique.
    PLoS One. 2017;12:e0181836.
    PubMed     Text format     Abstract available


  375. VAN LOO IHM, Dukers-Muijrers NHTM, Heuts R, van der Sande MAB, et al
    Screening for HIV, hepatitis B and syphilis on dried blood spots: A promising method to better reach hidden high-risk populations with self-collected sampling.
    PLoS One. 2017;12:e0186722.
    PubMed     Text format     Abstract available


  376. UEMURA H, Tsukada K, Mizushima D, Aoki T, et al
    Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
    PLoS One. 2017;12:e0186255.
    PubMed     Text format     Abstract available


  377. BURCHILL MA, Roby JA, Crochet N, Wind-Rotolo M, et al
    Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
    PLoS One. 2017;12:e0186213.
    PubMed     Text format     Abstract available


  378. LEE YL, Lin KY, Cheng CY, Li CW, et al
    Evolution of hepatitis A virus seroprevalence among HIV-positive adults in Taiwan.
    PLoS One. 2017;12:e0186338.
    PubMed     Text format     Abstract available


  379. LY HJ, Lokugamage N, Nishiyama S, Ikegami T, et al
    Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain.
    PLoS One. 2017;12:e0185194.
    PubMed     Text format     Abstract available


  380. LI T, Gao Y, Dong Q, Wang H, et al
    Degree sums and dense spanning trees.
    PLoS One. 2017;12:e0184912.
    PubMed     Text format     Abstract available


  381. DUFFY D, Mottez E, Ainsworth S, Buivan TP, et al
    An in vitro diagnostic certified point of care single nucleotide test for IL28B polymorphisms.
    PLoS One. 2017;12:e0183084.
    PubMed     Text format     Abstract available


  382. LUBYOVA B, Hodek J, Zabransky A, Prouzova H, et al
    PRMT5: A novel regulator of Hepatitis B virus replication and an arginine methylase of HBV core.
    PLoS One. 2017;12:e0186982.
    PubMed     Text format     Abstract available


  383. CHEN YI MEI SLG, Thompson AJ, Christensen B, Cunningham G, et al
    Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection.
    PLoS One. 2017;12:e0185609.
    PubMed     Text format     Abstract available


  384. YOON JG, Choi MJ, Yoon JW, Noh JY, et al
    Seroprevalence and disease burden of acute hepatitis A in adult population in South Korea.
    PLoS One. 2017;12:e0186257.
    PubMed     Text format     Abstract available


  385. PALIWAL D, Joshi P, Panda SK
    Hepatitis E Virus (HEV) egress: Role of BST2 (Tetherin) and interferon induced long non- coding RNA (lncRNA) BISPR.
    PLoS One. 2017;12:e0187334.
    PubMed     Text format     Abstract available


  386. OKA S, Furukawa H, Yasunami M, Kawasaki A, et al
    HLA-DRB1 and DQB1 alleles in Japanese type 1 autoimmune hepatitis: The predisposing role of the DR4/DR8 heterozygous genotype.
    PLoS One. 2017;12:e0187325.
    PubMed     Text format     Abstract available


  387. DULTZ G, Graubard BI, Martin P, Welker MW, et al
    Liver transplantation for chronic hepatitis C virus infection in the United States 2002-2014: An analysis of the UNOS/OPTN registry.
    PLoS One. 2017;12:e0186898.
    PubMed     Text format     Abstract available


  388. HARFOUCHE M, Chemaitelly H, Kouyoumjian SP, Mahmud S, et al
    Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions.
    PLoS One. 2017;12:e0187177.
    PubMed     Text format     Abstract available


  389. ROZERA G, Fabbri G, Lorenzini P, Mastrorosa I, et al
    Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals.
    PLoS One. 2017;12:e0187095.
    PubMed     Text format     Abstract available


  390. MAROT A, Henrion J, Knebel JF, Moreno C, et al
    Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
    PLoS One. 2017;12:e0186715.
    PubMed     Text format     Abstract available


  391. KONDILI LA, Gaeta GB, Brunetto MR, Di Leo A, et al
    Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.
    PLoS One. 2017;12:e0185728.
    PubMed     Text format     Abstract available


  392. LOGGI E, Galli S, Vitale G, Di Donato R, et al
    Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.
    PLoS One. 2017;12:e0187755.
    PubMed     Text format     Abstract available


  393. LANINI S, Minosse C, Vairo F, Garbuglia A, et al
    A large ongoing outbreak of hepatitis A predominantly affecting young males in Lazio, Italy; August 2016 - March 2017.
    PLoS One. 2017;12:e0185428.
    PubMed     Text format     Abstract available


  394. YOSHIOKA N, Deguchi M, Hagiya H, Kagita M, et al
    Durability of immunity by hepatitis B vaccine in Japanese health care workers depends on primary response titers and durations.
    PLoS One. 2017;12:e0187661.
    PubMed     Text format     Abstract available


  395. YANG Z, Jia M, Liu G, Hao H, et al
    Genomic sequencing identifies a few mutations driving the independent origin of primary liver tumors in a chronic hepatitis murine model.
    PLoS One. 2017;12:e0187551.
    PubMed     Text format     Abstract available


  396. RISALDE MA, Rivero-Juarez A, Romero-Palomo F, Frias M, et al
    Persistence of hepatitis E virus in the liver of non-viremic naturally infected wild boar.
    PLoS One. 2017;12:e0186858.
    PubMed     Text format     Abstract available


  397. KONERMAN MA, Lu D, Zhang Y, Thomson M, et al
    Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C.
    PLoS One. 2017;12:e0187344.
    PubMed     Text format     Abstract available


  398. XIAO H, Shi M, Xie Y, Chi X, et al
    Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0186660.
    PubMed     Text format     Abstract available


  399. YINDOM LM, Mendy M, Bodimeade C, Chambion C, et al
    KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians.
    PLoS One. 2017;12:e0188307.
    PubMed     Text format     Abstract available


  400. YANG A, Guo Z, Ren Q, Wu L, et al
    Active immunization in patients transplanted for hepatitis B virus related liver diseases: A prospective study.
    PLoS One. 2017;12:e0188190.
    PubMed     Text format     Abstract available


  401. SHIMIZU JF, Pereira CM, Bittar C, Batista MN, et al
    Multiple effects of toxins isolated from Crotalus durissus terrificus on the hepatitis C virus life cycle.
    PLoS One. 2017;12:e0187857.
    PubMed     Text format     Abstract available


  402. STROFFOLINI T, Sagnelli E, Andriulli A, Colloredo G, et al
    Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis.
    PLoS One. 2017;12:e0185710.
    PubMed     Text format     Abstract available


  403. GARRIGA C, Manzanares-Laya S, Garcia de Olalla P, Gorrindo P, et al
    Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns.
    PLoS One. 2017;12:e0187893.
    PubMed     Text format     Abstract available


  404. CARLUCCI JG, Farooq SA, Sizemore L, Rickles M, et al
    Low hepatitis C antibody screening rates among an insured population of Tennessean Baby Boomers.
    PLoS One. 2017;12:e0188624.
    PubMed     Text format     Abstract available


  405. BRAGA ACS, Carneiro BM, Batista MN, Akinaga MM, et al
    Heat shock proteins HSPB8 and DNAJC5B have HCV antiviral activity.
    PLoS One. 2017;12:e0188467.
    PubMed     Text format     Abstract available


  406. SPINA A, Lenglet A, Beversluis D, de Jong M, et al
    A large outbreak of Hepatitis E virus genotype 1 infection in an urban setting in Chad likely linked to household level transmission factors, 2016-2017.
    PLoS One. 2017;12:e0188240.
    PubMed     Text format     Abstract available


  407. LEE IC, Chau GY, Yeh YC, Chao Y, et al
    Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure.
    PLoS One. 2017;12:e0188552.
    PubMed     Text format     Abstract available


  408. LIM J, Kim K, Choi S, Park SM, et al
    The effectiveness and limitation of the national childhood hepatitis A vaccination program in the Republic of Korea: Findings from the Korean National Health and Nutrition Examination Survey (KNHANES), 2015.
    PLoS One. 2017;12:e0189210.
    PubMed     Text format     Abstract available


  409. MUNSHI SU, Tran TTT, Vo TNT, Tabassum S, et al
    Molecular characterization of hepatitis B virus in Bangladesh reveals a highly recombinant population.
    PLoS One. 2017;12:e0188944.
    PubMed     Text format     Abstract available


  410. CANGELOSI Q, Means SA, Ho H
    A multi-scale spatial model of hepatitis-B viral dynamics.
    PLoS One. 2017;12:e0188209.
    PubMed     Text format     Abstract available


  411. CANINI L, Imamura M, Kawakami Y, Uprichard SL, et al
    HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.
    PLoS One. 2017;12:e0187409.
    PubMed     Text format     Abstract available


  412. SMITH JW, Kroker-Lobos MF, Lazo M, Rivera-Andrade A, et al
    Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence.
    PLoS One. 2017;12:e0189255.
    PubMed     Text format     Abstract available


  413. COMSTOCK E, Kim CW, Murphy A, Emmanuel B, et al
    Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis.
    PLoS One. 2017;12:e0188314.
    PubMed     Text format     Abstract available


  414. YIN F, Xie Y, Fan H, Zhang J, et al
    Mutations in hepatitis B virus polymerase are associated with the postoperative survival of hepatocellular carcinoma patients.
    PLoS One. 2017;12:e0189730.
    PubMed     Text format     Abstract available


  415. PANNETIER J, Gigonzac V, Lydie N, Desgrees du Lou A, et al
    Timing of chronic hepatitis B diagnosis after migration and its determinants among Sub-Saharan African migrants living in France.
    PLoS One. 2017;12:e0189196.
    PubMed     Text format     Abstract available


  416. DERESSA T, Damtie D, Fonseca K, Gao S, et al
    The burden of hepatitis B virus (HBV) infection, genotypes and drug resistance mutations in human immunodeficiency virus-positive patients in Northwest Ethiopia.
    PLoS One. 2017;12:e0190149.
    PubMed     Text format     Abstract available


  417. BROQUETAS T, Garcia-Retortillo M, Hernandez JJ, Puigvehi M, et al
    Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues.
    PLoS One. 2017;12:e0188303.
    PubMed     Text format     Abstract available


  418. LAY P, An S, Soeung S, Srey PS, et al
    Ten year experience with antiretroviral treatment in Cambodia: Trends in patient characteristics and treatment outcomes.
    PLoS One. 2017;12:e0185348.
    PubMed     Text format     Abstract available


    January 2016
  419. YASUI Y, Abe T, Kurosaki M, Higuchi M, et al
    Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma.
    PLoS One. 2016;11:e0154558.
    PubMed     Text format     Abstract available


  420. BOCHAROV G, Meyerhans A, Bessonov N, Trofimchuk S, et al
    Spatiotemporal Dynamics of Virus Infection Spreading in Tissues.
    PLoS One. 2016;11:e0168576.
    PubMed     Text format     Abstract available


  421. DE MIGUEL-DIEZ J, Lopez-de-Andres A, Jimenez-Garcia R, Puente-Maestu L, et al
    Trends in Epidemiology of COPD in HIV-Infected Patients in Spain (1997-2012).
    PLoS One. 2016;11:e0166421.
    PubMed     Text format     Abstract available


  422. NJOKU OS, Manak MM, O'Connell RJ, Shutt AL, et al
    An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in Nigeria.
    PLoS One. 2016;11:e0166711.
    PubMed     Text format     Abstract available


  423. LIMA K, de Souza Leal E, Cavalcanti AM, Salustiano DM, et al
    Epidemiological, Clinical and Antiretroviral Susceptibility Characterization of Human Immunodeficiency Virus Subtypes B and Non-B in Pernambuco, Northeast Brazil.
    PLoS One. 2016;11:e0155854.
    PubMed     Text format     Abstract available


  424. BRUDER COSTA J, Dufeu-Duchesne T, Leroy V, Bertucci I, et al
    Pegylated Interferon alpha-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion.
    PLoS One. 2016;11:e0158297.
    PubMed     Text format     Abstract available


  425. PLAISTED WC, Zavala A, Hingco E, Tran H, et al
    Remyelination Is Correlated with Regulatory T Cell Induction Following Human Embryoid Body-Derived Neural Precursor Cell Transplantation in a Viral Model of Multiple Sclerosis.
    PLoS One. 2016;11:e0157620.
    PubMed     Text format     Abstract available


  426. FARSHADPOUR F, Taherkhani R, Tajbakhsh S, Gholizadeh Tangestani M, et al
    Prevalence and Trends of Transfusion-Transmissible Viral Infections among Blood Donors in South of Iran: An Eleven-Year Retrospective Study.
    PLoS One. 2016;11:e0157615.
    PubMed     Text format     Abstract available


  427. WU H, Padhi A, Xu J, Gong X, et al
    Evidence for Within-Host Genetic Recombination among the Human Pegiviral Strains in HIV Infected Subjects.
    PLoS One. 2016;11:e0161880.
    PubMed     Text format     Abstract available


  428. O'DONNELL PE, Ye XZ, DeChellis MA, Davis VM, et al
    Lipodystrophy, Diabetes and Normal Serum Insulin in PPARgamma-Deficient Neonatal Mice.
    PLoS One. 2016;11:e0160636.
    PubMed     Text format     Abstract available


  429. REMIS RS, Liu J, Loutfy MR, Tharao W, et al
    Prevalence of Sexually Transmitted Viral and Bacterial Infections in HIV-Positive and HIV-Negative Men Who Have Sex with Men in Toronto.
    PLoS One. 2016;11:e0158090.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: